PatientsVille.com Logo

Prostatectomy and Cialis

PatientsVille

Prostatectomy Symptoms and Causes

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American.

Symptoms of prostate cancer may include

  • Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
  • Low back pain
  • Pain with ejaculation

To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy.

Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments.

NIH: National Cancer Institute

Check out the latest treatments for prostatectomy

prostatectomy treatment research studies

Cialis clinical trials, surveys and public health registries


Find Drug Side Effect reports



Cialis Side Effects

Therapeutic Response Decreased (398)
Headache (367)
Vision Blurred (286)
Back Pain (260)
Myalgia (150)
Flushing (130)
Pain In Extremity (123)
Dizziness (121)
Visual Impairment (113)
Visual Acuity Reduced (111)
Optic Ischaemic Neuropathy (97)
Nasal Congestion (96)
Dyspepsia (92)
Visual Disturbance (88)
Nausea (85)
Insomnia (84)
Tinnitus (83)
Muscle Spasms (80)
Hypertension (76)
Arthralgia (67)
Visual Field Defect (48)
Erectile Dysfunction (47)
Loss Of Consciousness (46)
Gastrooesophageal Reflux Disease (42)
Asthenia (42)
Chest Pain (41)
Myocardial Infarction (41)
Pain (38)
Death (38)
Fatigue (38)
Ocular Hyperaemia (37)
Atrial Fibrillation (36)
Diarrhoea (34)
Dyspnoea (34)
Malaise (34)
Off Label Use (33)
Feeling Abnormal (31)
Blood Cholesterol Increased (31)
Cerebrovascular Accident (31)
Eye Pain (30)
Fall (30)
Hypotension (30)
Palpitations (30)
Priapism (29)
Blood Pressure Increased (28)
Diplopia (28)
Anxiety (27)
Eye Disorder (27)
Vomiting (27)
Prostate Cancer (27)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After taking Cialis I experienced nause and chest discomfort for two days so far, along with a pronounced feeling of general malaise and fatigue.

Cialis works for me. I like the product and I plan to get more at www.medsheaven.com

I get ankle swelling (peripheral edema ) ,nasal congestion, some facial redness for a while. but man, does it work. the swelling is a pain though.

I have taken 20mg doses of cialis 8 times, and have vomited 4 times within hours and have experienced nausea after all of them. I tend to find the drug SIGNIFICANTLY speeds up my heart rate to a worrying speed while any form of sexual contact sends i

I took viagra 4 times (50 mg) , it has a good effect, but the side effect was very much disturbing as if I got toxicity feeling and pain in my nerve system. I change to Cialis(10 mg). The effect is very good (the effect can be there up to 5 days

I was prescibed 2.5 mg Cialis daily for prostate cancer potency rehab. After three weeks, I expreienced a constant low grade headache, moderate muscle and joint pain and general fatigue. I also experienced some depression. As soon as I stopped t

Lowered blood pressure to 95/55. not a good feeling in stomache and slight headache. Not worth the misery as it lasted a good 24 hours although had a good erection

My Urologist gave some samples to try because of occasional ED. I tried this a couple of times now with the same result a massive headache and swelling sinuses like a major cold just descended on you in an instant. I felt terrible for a couple of da

The product worked for me too. It effect is indeed long, if you know it is also called 'weekend pill'. I buy my supply from ed-pharmacy-online.com and I'm pretty satisfied so far, do not register any side effects yet :)

Yes

Prostatectomy Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Brain SPECT Following Cialis (Tadalafil ) Administration
Condition: Change in Brain Perfusion
Intervention:
Outcome Measure:
2 Recruiting A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Conditions: Pulmonary Arterial Hypertension;   Systemic Sclerosis;   Scleroderma Spectrum of Diseases;   Connective Tissue Disease;   Pulmonary Hypertension
Interventions: Drug: Tadalafil monotherapy;   Drug: Ambrisentan monotherapy;   Drug: tadalafil and ambrisentan
Outcome Measures: To compare the effects of ambrisentan monotherapy, tadalafil monotherapy and the combination in patients with PAH-SSc on right ventricular mass as assessed by cardiac MRI and pulmonary vascular resistance (PVR) by right heart catheterization.;   To evaluate the safety of combination therapy with ambrisentan and tadalafil in PAH-SSc.;   To compare the change in: i. 6 MWD ii. Resting hemodynamics iii. Pressure/flow slopes with submaximal exercise iv. TAPSE by echocardiography v. Heart rate variability vi. Quality of life vii. Borg score viii. NYHA class
3 Recruiting A Study of Tadalafil for Duchenne Muscular Dystrophy
Condition: Muscular Dystrophy, Duchenne
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Change from Baseline in Six Minute Walk Distance (6MWD) in Meters;   Change from Baseline in the North Star Ambulatory Assessment (NSAA) Global Score;   Change from Baseline in Timed Function Tests in Seconds;   Time to Persistent 10% Worsening in 6MWD;   Time to Persistent 10% Worsening in Timed Function Tests;   Change from Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores;   Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil
4 Recruiting A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Period 1: Change from Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters;   Period 1: Time to First Occurence of Clinical Worsening (CW);   Period 2: Time to First Occurence of CW;   Period 2: Percentage of Participants Who Experience CW;   Period 1: Percentage of Participants Who Experience CW;   Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of tadalafil
5 Recruiting A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measure: Increase in immune response after tadalafil administration
6 Unknown  Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients
Condition: Single Ventricle
Interventions: Drug: Tadalafil Citrate;   Drug: Sugar pill
Outcome Measures: To compare the effects of Tadalafil versus placebo on exercise capacity (maximal oxygen consumption: VO2 max) for patients (8-35 years)with the Fontan circulation (8 -18 years).;   To evaluate the adverse effects of Tdalafil in patients (8-35 years)with the Fontan circulation and compare with the placebo group.
7 Not yet recruiting Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage
Conditions: Heart Failure;   Pulmonary Hypertension
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Change in renal function;   Incidence of acute kidney injury (AKI) events (clinical and subclinical);   Changes in renal function stratified by diabetes/no diabetes;   Incidence of AKI events stratified by diabetes/no diabetes
8 Recruiting The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
Condition: Fatigue
Interventions: Drug: Sildenafil;   Drug: tadalafil;   Drug: Placebo
Outcome Measures: Perceptual Fatigue;   Skeletal Muscle Fatigue;   Fractional Synthesis Rate
9 Recruiting A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
Condition: Lung Diseases, Interstitial
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Change in FVC (expressed as a percentage of the predicted value);   Improvement in dyspnoea (as measured by Mehler dyspnoea index);   Improvement in 6 min walk test;   change in DLCO;   change in total lung capacity;   change in the disability index of the Health Assessment Questionnaire (S HAQ);   change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36)scores
10 Recruiting A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
Conditions: Prostatic Hyperplasia;   Erectile Dysfunction
Interventions: Drug: 5 mg Tadalafil;   Drug: Placebo;   Drug: 0.2 mg Tamsulosin
Outcome Measures: Change from Baseline in Total International Prostate Symptom Score (IPSS) at Week 12;   Change from Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12;   Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12;   Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12;   Change from Baseline in IPSS at Week 12;   Change from Baseline in Uroflowmetry Measures at Week 12;   Change from Baseline in Postvoid Residual Volume (PVR) at Week 12;   Change from Baseline in IPSS Storage (Irritative) Subscore at Week 12;   Change from Baseline in IPSS Voiding (Obstructive) Subscore at Week 12;   Change from Baseline in IPSS Quality of Life (QoL) Index at Week 12;   Patient Global Impression of Improvement (PGI-I) at Week 12;   Clinician Global Impression of Improvement (CGI-I) at Week 12;   Change from Baseline in IIEF Overall Satisfaction at Week 12;   Change from Baseline in IIEF Intercourse Satisfaction at Week 12;   Change from Baseline in IIEF Orgasmic Function at Week 12;   Change from Baseline in IIEF Sexual Desire at Week 12;   Change from Baseline in IIEF Subscores at Week 12;   Change from Baseline in Total IPSS at Week 4 and Week 8;   Change from Baseline in IIEF EF at Week 4 and Week 8;   Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8;   Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8;   Change from Baseline in modified IPSS at Week 2
11 Recruiting Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study
Conditions: Aortic Stenosis;   LV Remodeling, Hypertrophy
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Change in LV mass on MRI;   Change in diastolic function as measured by tissue Doppler e';   Change in LV longitudinal peak systolic strain by echo;   Change in myocardial fibrosis (ECV) on MRI;   Change in other echocardiographic indices of diastolic function;   Safety and tolerability;   Change in indices of systolic function;   Change in LV hypertrophic remodeling;   Change in novel echocardiographic indices of diastolic function;   Change in 6 minute walk distance;   Change in circulating neurohormonal markers;   Change in quality of life;   Change in pulmonary artery pressure and pulmonary vascular resistance as assessed by echo;   Change in systemic blood pressure;   Change in RV function;   Change in AS severity
12 Recruiting Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
Conditions: Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Tadalafil;   Drug: placebo
Outcome Measures: Change in 6 minute walk test;   Maximum volume of oxygen extraction on exercise testing;   Pulmonary vascular resistance;   Mean pulmonary artery pressure;   Tricuspid annular plane excursion (TAPSE);   Dyspnea and health related quality of life (HRQL);   N-type brain natriuretic peptide (BNP) concentration;   Resting Hypoxemia;   Exercise-induced hypoxemia
13 Recruiting Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Conditions: Cardiomyopathy;   Renal Impairment
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Na excretion;   Change in GFR from baseline;   Change in urinary cGMP excretion
14 Not yet recruiting Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
Conditions: Cardiomyopathy;   Renal Impairment
Interventions: Drug: Tadalafil;   Drug: Placebo
Outcome Measures: Change in urinary sodium excretion;   Change in Glomerular Filtration Rate (GFR)
15 Recruiting Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
Condition: Congestive Heart Failure
Interventions: Drug: Nesiritide;   Drug: Tadalafil;   Drug: Placebo;   Drug: Saline load
Outcome Measures: Change in glomular filtration rate (GFR) at 60 minutes;   Change in urinary sodium excretion at 60 minutes;   Change in urinary cyclic guanosine monophosphate (cGMP) at 60 minutes
16 Recruiting A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Outcome Measures: Pharmacokinetics: Area under the concentration time curve for tadalafil;   Pharmacokinetics: Maximum plasma concentration for tadalafil;   Change from baseline to endpoint in World Health Organization (WHO) functional class;   Change from baseline to endpoint in 6 minute walk distance for participants greater than or equal to 7 years of age;   Percent increase from baseline to endpoint in N Terminal-Pro Brain Natriuretic Peptide (NT-Pro-BNP);   Percentage of participants with clinical worsening
17 Unknown  Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment
Condition: Erectile Dysfunction
Interventions: Drug: Sildenafil 100 mg;   Drug: Tadalafil 20 mg;   Drug: Combination half of maximal dose for sildenafil & tadalafil
Outcome Measures: International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score;   Erection Hardness Scale
18 Recruiting Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
Condition: Benign Prostate Hyperplasia
Interventions: Drug: Tadalafil;   Drug: Dutasteride
Outcome Measures: Area Under Curve (AUC) of tadalafil;   Cmax of tadalafil;   Area Under Curve (AUC) of dutasteride;   Cmax of dutasteride
19 Unknown  Efficacy and Safety of Tadalafil in Hemodialysis Patients
Condition: Erectile Dysfunction
Intervention: Drug: tadalafil
Outcome Measures: IIEF 5;   adverse effects reported
20 Recruiting Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMIL;   Drug: No aMIL
Outcome Measures: Progression free survival;   Toxicity;   Overall Survival